Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇦🇪AE · Science#112500 to 3K
- 🇰🇪KE · Science#135500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
500 to 3K🎙 ~2x weekly·57 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
1K to 6K🇦🇪50%🇰🇪50% - Active Followers
Loyal subscribers who consistently listen
400 to 2.4K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 14 epsHosts
Recent guests
Recent episodes
Prostate Cancer — Fifth Annual National General Medical Oncology Summit
Jun 23, 2026
Unknown duration
Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit
Jun 17, 2026
Unknown duration
Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Jun 16, 2026
Unknown duration
Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Jun 12, 2026
1h 28m 33s
Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Jun 5, 2026
22m 38s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/23/26 | Prostate Cancer — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:Introduction (0:00)Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)CME information and select publications | — | ||||||
| 6/17/26 | Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:Introduction (0:00)Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)CME information and select publications | — | ||||||
| 6/16/26 | Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting | Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:Introduction (0:00)Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)CME information and select publications | — | ||||||
| 6/12/26 | Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting✨ | renal cell carcinomacancer management+3 | Dr Thomas HutsonDr Eric A Singer+1 | Sarah Cannon Research InstituteThe Ohio State University Comprehensive Cancer Center+1 | — | renal cell carcinomacancer treatment+3 | — | 1h 28m 33s | |
| 6/5/26 | Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays✨ | genitourinary cancerscirculating tumor DNA+3 | Professor Thomas Powles | Barts Cancer Institute | London, United Kingdom | circulating tumor DNAurothelial bladder cancer+3 | — | 22m 38s | |
| 5/26/26 | Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays✨ | genitourinary cancerscirculating tumor DNA+3 | Professor Thomas Powles | Barts Cancer Institute | London, United Kingdom | circulating tumor DNAurothelial bladder cancer+3 | — | 29m 57s | |
| 5/15/26 | PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida✨ | PARP inhibitorshormone-sensitive prostate cancer+3 | Dr Wassim Abida | Memorial Sloan Kettering Cancer Center | New York | PARP inhibitorshormone-sensitive+3 | — | 51m 55s | |
| 4/17/26 | Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances✨ | prostate cancertherapy selection+3 | Dr Andrew J ArmstrongDr Scott T Tagawa | Duke Cancer InstituteWeill Cornell Medicine Meyer Cancer Center | Durham, North CarolinaNew York, New York | prostate cancertherapy sequencing+3 | — | 58m 21s | |
| 4/15/26 | Metastatic Bladder Cancer — Rapid Case Review Issue 4✨ | metastatic bladder cancerpatient cases+3 | Dr Matthew Milowsky | UNC Lineberger Comprehensive Cancer CenterEmory University School of Medicine+1 | — | metastatic bladder cancerurothelial cancer+3 | — | 27m 45s | |
| 3/31/26 | AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium✨ | AKT inhibitionprostate cancer+3 | Prof Karim FizaziDr Daniel George | Centre Oscar LambretDuke Cancer Institute+1 | — | AKT inhibitionprostate cancer+3 | — | 1h 29m 22s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 3/27/26 | Metastatic Bladder Cancer — Rapid Case Review Issue 3✨ | metastatic bladder cancerpatient cases+3 | Dr Matthew Milowsky | UNC Lineberger Comprehensive Cancer CenterEmory University School of Medicine+1 | — | metastatic bladder cancerurothelial cancer+3 | — | 32m 43s | |
| 3/25/26 | Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium✨ | bladder cancernon-muscle-invasive cancer+3 | Dr Matthew D GalskyDr Shilpa Gupta+1 | The Tisch Cancer InstituteCleveland Clinic’s Taussig Cancer Institute+2 | — | bladder cancernon-muscle-invasive+3 | — | 1h 58m 06s | |
| 2/23/26 | Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review✨ | bladder cancertherapy selection+3 | Dr Terence Friedlander | — | — | urothelial bladder cancertherapy sequencing+3 | — | 23m 29s | |
| 2/17/26 | Metastatic Bladder Cancer — Rapid Case Review Issue 2✨ | metastatic bladder cancerpatient cases+3 | Dr Fern AnariDr Catherine Fahey | Fox Chase Cancer CenterLineberger Comprehensive Cancer Center+1 | Philadelphia, PennsylvaniaChapel Hill, North Carolina+1 | metastatic bladder cancerpatient cases+3 | — | 29m 11s | |
| 2/10/26 | Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review✨ | prostate cancerandrogen pathway-targeting agents+3 | Dr Rana R McKay | ESMO Congress 2025 | — | prostate cancerandrogen pathway+3 | — | 18m 06s | |
| 2/4/26 | Urothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 Review✨ | bladder cancertherapy selection+3 | Dr Terence Friedlander | — | — | urothelial bladder cancertherapy sequencing+3 | — | 31m 09s | |
| 1/29/26 | Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review✨ | prostate cancertherapy selection+3 | Dr Rana R McKay | ESMO Congress 2025 | — | prostate cancertherapy sequencing+3 | — | 18m 08s | |
| 1/23/26 | Metastatic Bladder Cancer — Rapid Case Review Issue 1 | Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here. | — | ||||||
| 12/19/25 | Urothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual Meeting | Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.CME information and select publications here. | — | ||||||
| 11/11/25 | Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute | Dr Emmanuel S Antonarakis and Dr Matthew R Smith share their perspectives on the evolving therapeutic landscape for patients with prostate cancer. CME information and select publications here. | — | ||||||
| 9/22/25 | Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management | Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here. | — | ||||||
| 7/31/25 | Oncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient Care | Ms Kathleen D Burns from City of Hope Comprehensive Cancer Center in Duarte, California, discusses nursing considerations in the care of patients with prostate cancer. NCPD information and select publications here. | — | ||||||
| 7/24/25 | Renal Cell Carcinoma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting | Prof Laurence Albiges and Dr Tian Zhang summarize major findings presented at the 2025 ASCO Annual Meeting and review relevant ongoing clinical trials for patients with renal cell carcinoma. CME information and select publications here. | — | ||||||
| 7/15/25 | For Oncology Nurses: Prostate Cancer — Proceedings from the 2025 Annual ONS Congress | Dr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here. | — | ||||||
| 7/11/25 | Urothelial Bladder Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting | Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Prof Andrea Necchi from the IRCCS San Raffaele Hospital in Milan, Italy, and Prof Thomas Powles from the Barts Cancer Institute in London provide their perspectives on clinical scenarios and datasets informing the care of patients with urothelial bladder cancer. CME information and select publications here. | — | ||||||
Showing 25 of 65
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.